Imfinzi may be used to treat patients with advanced cancer bladder whose illness has advanced despite chemotherapy. The average wholesale acquisition price for the drug is about $15,000 a month, according to AstraZeneca.
While this decision marks the first approved use for the immunotherapy drug, AstraZeneca is also exploring Imfinzi’s efficacy to treat lung cancer.
More articles on supply chain:
FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps